Safety
SAEs, pharyngalgia, dermatitis, TEAEs
ADVERSE EVENTS, DERMATITIS, SEQUELAE, DISORDERS
All the participants received a single dose of JMB2002 over the range of 5 to 50 mg/kg or placebo by intravenous infusion. Within the entire duration of the study, a total of 17 (42.5%) participants developed 27 cases of TEAEs, including 13 (40.6%) in the test groups and 4 (50%) in the control group. Among them, 11 (27.5%) participants developed 17 drug-related TEAEs, including 8 (25.0%) in the test groups and 3 (37.5%) in control group (Table 
Treatment emergent adverse events after a single-dose infusion of JMB2002Abbreviations: TRAEs, Treatment related adverse eventsNo participants developed grade ≥ 3 TEAEs, grade ≥ 3 drug-related TEAEs, SAEs or drug-related SAEs. Except 1 participant in the test group at 50 mg/kg dose level developed 2 grade 2 drug-related TEAEs, which included “general disorders and administration site conditions/chest discomfort” and “vascular and lymphatic disorders/flushing”, all the other drug-related TEAEs were grade 1. All the participants with TEAEs recovered without sequelae, except for 1 case of “dermatitis” and 1 case of “pharyngalgia” that were determined to be “unlikely related” to the study drug (Table 
TEAEs summarized by MedDAR system organ, preferred termAbbreviations: ALT, alanine aminotransferase; TRAEs, Treatment related adverse events